ClinicalTrials.gg
RecruitingNCT06026943Updated Jun 16, 2026

Alpha Radiation Emitters for the Treatment of Pancreatic Cancer for the Treatment of Locally Advanced Pancreatic Cancer

An interventional study of DaRT seeds insertion in Pancreatic Cancer, Unresectable Pancreatic Cancer and Pancreatic Adenocarcinoma, sponsored by Alpha Tau Medical LTD.. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by Alpha Tau Medical LTD. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 214 studies in Pancreatic Neoplasms with a site in Italy — 52 open to participants now, 76 under way, 11 of them phase 3. Pancreatic Neoplasms · Italy.

Planned enrollment
148th of 157
15 · median 154
Started
2026
with 11 others
No phase
43 of 214
12 open now
Primary completion
2027-01
later than 33 of 75 live
Registered
163rd of 214
by date

Among the 214 studies in Pancreatic Neoplasms with a site in Italy, this one is the 148th largest by planned enrollment of the 157 interventional ones that give a count, is one of 12 that started in 2026, is one of 43 with no phase, reaches primary completion later than 33 of the 75 other live ones, and was the 163rd registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

52 of the 214 studies in Pancreatic Neoplasms with a site in Italy are open now. Recruiting first, the newest first:

46 more — sign in →

All 52 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 120 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 214 studies in Pancreatic Neoplasms with a site in Italy, or all of them as a file.
02

Study summary

A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for advanced pancreatic cancer

Read the detailed description

This is a prospective, interventional, single-center, open label, single arm study. The study is designed to evaluate the feasibility and Safety of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Locally Advanced Pancreatic Cancer

The study will be comprised of a screening period, DaRT insertion visit, 3 months follow up per subject and 2 years for accrual and trial completion. The total duration of the study will be 24 months from the DaRT insertion procedure.

15 patients with a safety interim analysis after the 5 first patients . patients with advanced pancreatic cancer will be recruited by the investigational site.

Eligible patients who meet inclusion/exclusion criteria (as assessed during the screening period) will be invited to the site for the procedure of DaRT seeds insertion.

03

Conditions studied

  • Pancreatic Cancer
  • Unresectable Pancreatic Cancer
  • Pancreatic Adenocarcinoma

Keywords

  • pancreatic cancer
  • Unresectable Pancreatic Cancer
  • Pancreatic Adenocarcinoma
  • Alpha radiation
  • Pancreas Cancer
04

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • and/or cytologically proven NCCN locally advanced PC
  • Patients must have i) received at least one (any kind) OR ii) are medically unfit for further chemotherapy, AND iii) the tumor is still not deemed as resectable with radical surgery, or the patient does not wish to go through surgery.
  • DaRT indication validated by a multidisciplinary team.
  • per (version 1.1) criteria
  • TC at Verona's center (not been over a month)
  • Lesion size ≤ 5 cm in the longest diameter
  • Age ≥18 years old
  • Performance Status Scale ≤ 2
  • is more than 6 months
  • WBC ≥ 3500/μl, granulocyte ≥ 1500/μl
  • count ≥60,000/μl
  • Calculated or measured ≥ 30cc/min. Calculated or measured creatinine clearance can be ≥ 40cc/min given stability of creatinine levels over the past three weeks (at least 1 test per week).
  • and ALT ≤ 2.5 X (ULN)
  • \< 1.4 for patients not on Warfarin
  • Subjects are willing and able to sign an form
  • Women of (WOCBP) will have evidence of negative pregnancy test before the Ra-224 implantation and are required to use an acceptable method to prevent pregnancy for 3 months after brachytherapy.
  • Patients must agree to use adequate contraception (vasectomy or barrier method of birth control) prior to study entry, for the duration of study participation and for 3 months after discontinuing therapy.

Exclusion criteria

Exclusion Criteria:

  • Concomitant chemotherapy or immunotherapy within the past 4 weeks
  • Prior radiation therapy to the pancreas
  • CA 19-9 > 1000 Units/ml
  • Fit for surgical exploration unless the patient refuses surgery
  • Known to any of the components of the treatment.
  • Patients undergoing systemic therapy excepting intermittent, brief use of systemic .
  • cardiovascular disease, e.g. cardiac failure of classes III-IV, uncontrolled coronary artery disease, cardiomyopathy, uncontrolled arrhythmia, uncontrolled hypertension, or history of myocardial infarction in the last 12 months.
  • Patients with uncontrolled intercurrent illnesses including, but not limited to an active infection requiring systemic therapy (not including cholangitis) or a known psychiatric or substance abuse disorder(s) that would interfere with cooperation with the requirements of the trial or interfere with the study endpoints.
  • Has a known additional that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
  • Patient requires treatment not specified in this protocol which may conflict with the endpoints of this study including evaluation of response or toxicity of DaRT.
  • Patients do not agree to use adequate (vasectomy or barrier method of birth control) prior to study entry, for the duration of study participation and for 3 months after discontinuing therapy.
  • Volunteers participating in another interventional study in the past 30 days which might conflict with the endpoints of this study or the evaluation of response or toxicity of DaRT.
  • High probability of protocol non-compliance (in opinion of investigator).
  • Breastfeeding women or women of unwilling or unable to use an acceptable contraceptive method to prevent pregnancy for 3 months after RT.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    DaRT Seeds

    Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds

    Device: DaRT seeds insertion

Interventions

  • DeviceDaRT seeds insertion

    An intratumoral insertion of radioactive sources \[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms

    Also known as: Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)

06

What researchers measure

Primary outcomes

  1. Feasibility- DaRT seed placement

    Feasibility will be determined according to the rate of successful placement of DaRT seeds via imaging

    Time frame: Immediately following the insertion procedure

  2. Safety- Adverse events, Safety will be determined according to the overall incidence of device-related SAE's graded according to CTCAE v5.0 criteria

    Safety will be determined according to the overall incidence of device-related SAE's graded according to CTCAE v5.0 criteria

    Time frame: from DaRT-insertion up to 48 hours

Secondary outcomes

  1. To evaluate the Efficacy of the Alpha DaRT seeds for locally advanced pancreatic cancer

    Local control evaluation according to RECIST v1.1

    Time frame: 1 months and 3 months

  2. To evaluate the Efficacy of the Alpha DaRT seeds by measuring the CA-19-9 markers levels

    Change in CA 19-9 levels

    Time frame: 1 months and 3 months

  3. Efficacy - to evaluate what is the percent of the Tumor Coverage by the Alpha DaRT seeds

    Tumor Coverage

    Time frame: immediately following the insertion procedure]

  4. Efficacy- Alpha DaRT seeds

    Overall incidence of device-related SAE's graded according to CTCAE v5.0 criteria

    Time frame: from DaRT-insertion up to initiation of a possible postablation therapy or up to a maximum three months

Other outcomes

  1. Exploratory Objective -to evaluate the changes in the immune markers by Blood samples for immune response

    Changes in immune markers following treatment ,These biomarkers include: * CD3 * CD4 * CD8 * CD69 * CD137

    Time frame: 1 month

07

Study locations

1 of 1 sites recruiting
  • Chirurgia Generale e del Pancreas, Istituto del Pancreas
    Verona, Italy
    Recruiting
    • Salvatore Paiella, MD · Contact045-8124553
    • Erica Secchettin · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Jan 2027, 8 months after the start.

Of 432 interventional studies with no phase under Pancreatic Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 75. This study's planned 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2023
First posted
Sep 7, 2023
StartActual
May 6, 2026
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2028
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06026943
Responsible party
Sponsor
First posted
Sep 7, 2023
Start date
May 6, 2026
Primary completion
Jan 2027 (estimated)
Completion
Jan 2028 (estimated)
Last update
Jun 16, 2026

Study contacts

Liron Dimnik
Contact
LironD@alphatau.com
+972-2-3737-7000
Salvatore Paiella, MD
principal investigator · Pancreas Institute - Integrated University Hospital of Verona

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion